Cagrilintide and Semaglutide: the Combination Weight-Loss Treatment Being Watched Closely

You've read about a new combination jab and you want to know whether it's real

The coverage started a couple of years ago, and since then the questions haven't stopped. A question our prescribers hear most weeks, in various forms, is: "I've seen something about a new injection that beats Wegovy, can I get it?" The honest answer in mid-2026 is: not yet, and not in the UK through any legitimate route.

CagriSema is the working name for a fixed weekly injection that delivers cagrilintide and semaglutide together at a 2.4 mg to 2.4 mg ratio. Cagrilintide is a long-acting analogue of amylin, a hormone made by the pancreas that works alongside insulin to slow stomach emptying and signal fullness to the brain. Semaglutide (the active ingredient already in Wegovy injection) mimics GLP-1, a gut hormone that suppresses appetite and slows gastric emptying through a different receptor system. The rationale for combining them is that two complementary signals may suppress appetite more durably than either alone.

Novo Nordisk moved the combination into a large phase-three programme called REDEFINE. Initial results reported in early 2025 showed average weight loss of around 22–23% over 68 weeks in adults with obesity, compared with roughly 15% for semaglutide 2.4 mg alone in its own pivotal trials. That is a meaningful difference on paper. The caveat is that those trial programmes were run separately, in different populations, so they are not a direct head-to-head comparison, an important distinction when reading headlines.

How cagrilintide's mechanism differs from anything currently licensed in the UK

The UK currently has two GLP-1 based injectable weight-loss medicines with a marketing authorisation: Wegovy (semaglutide) and Mounjaro (tirzepatide). Tirzepatide already activates two receptors (GLP-1 and GIP) which is why it is described as a dual agonist. CagriSema adds a third route entirely by bringing in the amylin system.

Amylin is released from beta cells at the same time as insulin. It acts on receptors in the brainstem and hypothalamus to reduce food intake, blunt the speed at which the stomach empties, and suppress glucagon (the hormone that raises blood sugar). People with obesity sometimes show blunted amylin signalling, which may partly explain why hunger returns quickly after eating. Cagrilintide is designed to restore that signal in a sustained way across the week.

The practical implication is that combining an amylin pathway drug with a GLP-1 drug could address appetite through routes that do not fully overlap. Semaglutide is very effective at reducing appetite and slowing gastric emptying, but amylin receptors sit in different parts of the brain. Whether that distinction translates to meaningfully better outcomes in real-world patients (and at what side-effect cost) is what the REDEFINE programme is trying to determine. The full trial dataset, including cardiovascular and long-term maintenance outcomes, will be part of any regulatory submission.

Where the regulatory process stands, and why that matters before you plan around it

As of July 2026, Novo Nordisk had not submitted a marketing authorisation application to the MHRA for CagriSema as a UK weight-management treatment. Regulatory timelines for a novel combination medicine typically run 12 to 18 months from submission, and require the agency to assess not just efficacy but safety, manufacturing standards and the proposed patient information materials. A licensed medicine then goes to NICE for an appraisal before NHS commissioning can follow. That process, as it unfolded for semaglutide and tirzepatide, took additional years after the original licence.

What this means practically: people who are managing their weight now and want to act now have a different set of options. Wegovy at 2.4 mg, and the newly approved 7.2 mg maintenance dose approved by the MHRA in April 2026, are already available as licensed medicines, as is tirzepatide (Mounjaro). If you are also curious about the 20ml semaglutide format and what it involves, that is worth reading before comparing options and providers. The cost of Wegovy in the UK varies by dose and provider, and it is worth understanding what a private prescription legitimately includes before comparing prices.

You can review what licensed weight-loss treatments are currently available through the NICE appraisal guidance on semaglutide for weight management at NICE TA875, and through the NHS medicines page for semaglutide, which covers the licensed indications, how the medicine is taken, and its side-effect profile. Both are useful reference points if you are weighing current options against what may arrive in future.

Side effects and what the trial data suggest about the combination's tolerability

Any new combination medicine carries the question of whether it adds side effects as well as benefits. The REDEFINE trial data reported gastrointestinal side effects (nausea, vomiting, diarrhoea, constipation) as the most common, broadly consistent with the profile seen with semaglutide alone. Some analyses suggested the rates were somewhat higher with CagriSema, particularly in early titration, though most events were described as mild to moderate and transient. That is an expected finding when adding a second appetite-suppressing mechanism.

Cagrilintide on its own, in earlier trials, produced similar GI side effects to other injectable appetite medicines. There is no specific MHRA safety communication for cagrilintide as a licensed UK product yet, because there is no licensed product. Once any application is submitted and reviewed, the agency will publish its assessment.

If you are currently on semaglutide and experiencing side effects, the right step is to speak to your prescriber rather than wait for a future medicine. The most common concerns about injectable weight-loss treatment are ones that an experienced prescriber has managed before. Dose titration, timing and lifestyle adjustments all play a role in tolerability, and that is a conversation worth having now rather than deferring while you wait for regulatory news. When you're ready to explore what's licensed and available today, checking your eligibility with our clinical team is a straightforward starting point.